retatrutide triple agonist gip glp-1 glucagon phase 2 obesity is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Retatrutide for weight loss: Study
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15






















